INIS · International Isotopes Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.38M | - | $3.28M | $3.66M | $3.24M | - | $3.92M | $3.17M | $2.90M | - |
| Cost of Revenue | $1.23M | - | $1.34M | $1.51M | $1.21M | - | $1.48M | $1.15M | $1.04M | - |
| Gross Profit | $1.15M | - | $1.94M | $2.14M | $2.03M | - | $2.45M | $2.02M | $1.87M | - |
| R&D | $149.1K | - | $139.4K | $102.7K | $106.7K | - | $112.4K | $188.7K | $188.2K | - |
| SG&A | $1.01M | - | $821.6K | $1.08M | $871.0K | - | $1.08M | $1.05M | $1.00M | - |
| Total Operating Expenses | $2.46M | - | $2.12M | $2.28M | $2.10M | - | $2.27M | $2.20M | $2.13M | - |
| D&A | $110.2K | - | $100.7K | $101.0K | $97.9K | - | $100.8K | $99.0K | $101.4K | - |
| Operating Income | ($1.31M) | - | ($181.4K) | ($134.8K) | ($65.0K) | - | $179.6K | ($180.1K) | ($266.2K) | - |
| Interest Expense | $84.9K | - | $86.3K | $82.8K | $81.3K | - | $81.9K | $81.5K | $81.3K | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($1.35M) | - | ($203.6K) | ($160.8K) | ($112.7K) | - | $150.3K | ($233.4K) | ($154.1K) | - |
| EPS - Basic | $0.00 | - | $0.00 | $0.00 | $0.00 | - | $0.00 | $0.00 | $0.00 | - |
| EPS - Diluted | $0.00 | - | $0.00 | $0.00 | $0.00 | - | $0.00 | $0.00 | $0.00 | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.35M | $1.70M | $1.65M | $1.86M | $1.65M | $1.95M | $2.37M | $2.19M | $2.37M | $2.69M |
| Accounts Receivable | $1.27M | $1.42M | $1.97M | $1.73M | $1.69M | $1.52M | $1.47M | $1.14M | $1.36M | $1.47M |
| Inventory | $831.9K | $875.4K | $1.05M | $670.5K | $723.5K | $820.9K | $845.0K | $699.3K | $934.2K | $927.1K |
| Accounts Payable | $1.86M | $1.53M | $1.22M | $935.0K | $321.9K | $861.9K | $607.7K | $312.2K | $671.4K | $559.6K |
| Current Assets | $3.92M | $4.63M | $4.98M | $4.57M | $4.56M | $4.99M | $5.18M | $4.34M | $5.14M | $5.76M |
| Total Assets | $17.19M | $17.84M | $17.85M | $17.51M | $17.57M | $17.16M | $16.70M | $15.92M | $16.82M | $16.91M |
| Current Liabilities | $4.45M | $3.97M | $3.69M | $3.11M | $4.63M | $3.33M | $3.27M | $6.71M | $7.33M | $3.27M |
| Long-term Debt | - | $1.93M | - | - | - | $2.21M | - | - | - | $2.05M |
| Total Liabilities | $14.54M | $14.14M | $13.75M | $13.24M | $13.23M | $12.81M | $12.67M | $12.10M | $12.78M | $12.87M |
| Stockholders' Equity | $2.65M | $3.69M | $4.10M | $4.27M | $4.34M | $4.35M | $4.04M | $3.83M | $4.04M | $4.04M |
| Retained Earnings | ($129.58M) | ($128.23M) | ($127.80M) | ($127.59M) | ($127.43M) | ($127.32M) | ($127.57M) | ($127.72M) | ($127.48M) | ($127.33M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($72.4K) | - | - | - | ($5.1K) | - | - | - | $412.4K | - |
| Investing Cash Flow | ($205.2K) | - | - | - | ($128.9K) | - | - | - | ($170.9K) | - |
| Financing Cash Flow | ($56.8K) | - | - | - | ($150.6K) | - | - | - | ($63.6K) | - |
| CapEx | $205.2K | - | $64.0K | $61.5K | $128.9K | - | $44.0K | $44.0K | $170.9K | - |
| Free Cash Flow | ($277.6K) | - | - | - | ($134.0K) | - | - | - | $241.5K | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 48.4% | - | 59.2% | 58.6% | 62.7% | - | 62.4% | 63.7% | 64.2% | - |
| Operating margin | -55.1% | - | -5.5% | -3.7% | -2.0% | - | 4.6% | -5.7% | -9.2% | - |
| EBITDA margin | -50.4% | - | -2.5% | -0.9% | 1.0% | - | 7.1% | -2.6% | -5.7% | - |
| Net margin | -56.7% | - | -6.2% | -4.4% | -3.5% | - | 3.8% | -7.4% | -5.3% | - |
| Free cash flow margin | -11.7% | - | - | - | -4.1% | - | - | - | 8.3% | - |
| FCF / Net income | 0.21 | - | - | - | 1.19 | - | - | - | -1.57 | - |
| R&D / Revenue | 6.3% | - | 4.3% | 2.8% | 3.3% | - | 2.9% | 6.0% | 6.5% | - |
| SG&A / Revenue | 42.6% | - | 25.1% | 29.7% | 26.9% | - | 27.6% | 33.0% | 34.6% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -7.8% | - | -1.1% | -0.9% | -0.6% | - | 0.9% | -1.5% | -0.9% | - |
| Return on equity | -50.9% | - | -5.0% | -3.8% | -2.6% | - | 3.7% | -6.1% | -3.8% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.88 | 1.16 | 1.35 | 1.47 | 0.99 | 1.50 | 1.58 | 0.65 | 0.70 | 1.76 |
| Quick ratio | 0.69 | 0.94 | 1.06 | 1.26 | 0.83 | 1.25 | 1.32 | 0.54 | 0.57 | 1.48 |
| Cash ratio | 0.30 | 0.43 | 0.45 | 0.60 | 0.36 | 0.58 | 0.73 | 0.33 | 0.32 | 0.82 |
| Leverage | ||||||||||
| Debt / Equity | - | 0.52 | - | - | - | 0.51 | - | - | - | 0.51 |
| Debt / Assets | - | 0.11 | - | - | - | 0.13 | - | - | - | 0.12 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -15.4x | - | -2.1x | -1.6x | -0.8x | - | 2.2x | -2.2x | -3.3x | - |
| Equity multiplier | 6.49 | 4.83 | 4.36 | 4.10 | 4.05 | 3.95 | 4.14 | 4.16 | 4.17 | 4.19 |
| Liabilities / Assets | 0.85 | 0.79 | 0.77 | 0.76 | 0.75 | 0.75 | 0.76 | 0.76 | 0.76 | 0.76 |
| Efficiency | ||||||||||
| Asset turnover | 0.14 | - | 0.18 | 0.21 | 0.18 | - | 0.23 | 0.20 | 0.17 | - |
| Inventory turnover | 1.48 | - | 1.27 | 2.26 | 1.67 | - | 1.75 | 1.65 | 1.11 | - |
| Days sales outstanding | 195d | - | 219d | 173d | 190d | - | 137d | 131d | 170d | - |
| Days inventory outstanding | 247d | - | 286d | 162d | 219d | - | 209d | 222d | 328d | - |
| Days payable outstanding | 554d | - | 333d | 225d | 97d | - | 150d | 99d | 236d | - |
| Cash conversion cycle | -111d | - | 173d | 109d | 312d | - | 196d | 253d | 263d | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 16.0x | - | 7.7x | 9.9x | 6.0x | - | 5.2x | 4.1x | 5.2x | - |
| P / S | 17.8x | - | 9.7x | 11.5x | 8.1x | - | 5.3x | 4.9x | 7.2x | - |
| EV / EBITDA | - | - | - | - | 745.8x | - | 66.2x | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -26.6% | - | -16.5% | 15.3% | 11.5% | - | 34.5% | 1.8% | -6.0% | - |
| Revenue CAGR (3y) | -8.3% | - | 5.5% | 14.5% | 4.9% | - | 14.5% | 4.7% | 13.4% | - |
| Revenue CAGR (5y) | 3.6% | - | 2.7% | 11.1% | 6.8% | - | 10.9% | 8.2% | 2.8% | - |
| Gross profit growth (YoY) | -43.4% | - | -20.8% | 6.1% | 8.9% | - | 36.6% | 9.5% | 4.8% | - |
| Operating income growth (YoY) | -1914.9% | - | - | 25.1% | 75.6% | - | - | 21.2% | -80.4% | - |
| Net income growth (YoY) | -1096.2% | - | - | 31.1% | 26.8% | - | - | 11.3% | -4.1% | - |
| EPS growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | -107.2% | - | - | - | - | - | - | - | -74.0% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -39.0% | -15.1% | 1.5% | 11.4% | 7.5% | 7.7% | -1.1% | -11.8% | -9.2% | -7.0% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$13.07M totalTheranostics Products$6.84M · 52.3%
Calibration Reference Products$4.25M · 32.5%
Cobalt Products$1.75M · 13.4%
Medical Device Products$229.0K · 1.8%
Peer comparison
Same SIC group: Industrial Instruments For Measurement, Display, and Control
Comparing INTERNATIONAL ISOTOPES INC against the 5 most active filers in the same SIC group.